CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its participation in an industry panel discussion at the Canaccord Adams' Hepatitis C Conference on Thursday, April 1, 2010 at 3:00 p.m. EDT.
The panel will be webcast live and may be accessed from ‘Events & Presentations’ on the home page of Vertex’s website at www.vrtx.com. A replay of the webcast will also be available on the Company’s website for two weeks following the presentation. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company’s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, epilepsy, cancer, and pain. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.
Lexiva is a registered trademark of the GlaxoSmithKline group of companies.
Vertex’s press releases are available at www.vrtx.com.
(VRTX-WEB)
CONTACT:
Vertex Pharmaceuticals Incorporated
Lora Pike, 617-444-6755
Director, Investor Relations
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Infectious Diseases Oncology Pharmaceutical
MEDIA:
| Logo |